# Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

> **NCT00473083** · PHASE2 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 150 (actual)

## Conditions studied

- Rash

## Interventions

- **DRUG:** Minocycline
- **DRUG:** Clindamycin 2% in hydrocortisone 1% lotion
- **DRUG:** Erlotinib
- **DRUG:** Topical clindamycin 2%, triamcinolone acetonide 0.1% soln

## Key facts

- **NCT ID:** NCT00473083
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473083, "Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00473083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*